Titre:pro newsletter archive | mapi: health research & commercialization
La description :pro newsletter archive | mapi: health research & commercialization...
Classement Alexa Global: # 14,030,680
Server:Apache...
L'adresse IP principale: 104.27.157.194,Votre serveur Singapore,Singapore ISP:CloudFlare Inc. TLD:com Code postal:sg
Ce rapport est mis à jour en 26-Jul-2018
Created Date: | 2007-08-21 |
Changed Date: | 2017-06-26 |
Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte pro-newsletter.com.Actuellement, hébergé dans Singapore et son fournisseur de services est CloudFlare Inc. .
Latitude: | 1.2896699905396 |
Longitude: | 103.85006713867 |
Pays: | Singapore (sg) |
Ville: | Singapore |
Région: | Singapore |
ISP: | CloudFlare Inc. |
domaine | Titre |
---|---|
pro-newsletter.com | pro newsletter archive | mapi: health research & commercialization |
waltham.com | waltham science research pet dog cat health nutrition well being |
nootriment.com | nootriment - health supplement reviews and research |
well-beingsecrets.com | research-backed articles about nutrition and health in general |
marseille-maider.org | mm health | health articles | health center | health food | health insurance |
united-healthcare.co | universal health blog | health blog,health bloggers,health blogspot,health blogs |
helathcenter.com | health tips | fitness & health life ideas | health care news | home remedies - g |
healthcareinternational.net | health care international - health news, health blogs |
resarch.info | info-tech research group – it research & advisory services |
ameriresearch.com | ameri research inc. | global market research reports | industry analysis |
brasilresearch.com | brasil research - full service market research company |
spreadresearch.com | first independent european credit research agency – spread research |
innovaderm.ca | innovaderm research | dermatology contract research organization cro |
buy-peptides.us | righteous research peptides and research chemicals · righteous research |
faculty-psbedu.paris | psb faculty & research | research for practice |
Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.
X-TEC-API-ROOT: | https://mapigroup.com/wp-json/tribe/events/v1/ |
Transfer-Encoding: | chunked |
Expires: | Wed, 11 Jan 1984 05:00:00 GMT |
Connection: | close |
Server: | Apache |
X-TEC-API-VERSION: | v1 |
X-TEC-API-ORIGIN: | https://mapigroup.com |
Link: | |
Cache-Control: | no-cache, must-revalidate, max-age=0 |
Date: | Wed, 25 Jul 2018 23:29:51 GMT |
Content-Type: | text/html; charset=UTF-8 |
soa: | brit.ns.cloudflare.com. dns.cloudflare.com. 2028111209 10000 2400 604800 3600 |
ns: | brit.ns.cloudflare.com. cory.ns.cloudflare.com. |
mx: | MX preference = 10, mail exchanger = spool.mail.gandi.net. MX preference = 50, mail exchanger = fb.mail.gandi.net. |
ipv4: | IP:104.27.157.194 ASN:13335 OWNER:CLOUDFLARENET - Cloudflare, Inc., US Country:US IP:104.27.156.194 ASN:13335 OWNER:CLOUDFLARENET - Cloudflare, Inc., US Country:US |
ipv6: | 2400:cb00:2048:1::681b:9dc2//13335//CLOUDFLARENET - Cloudflare, Inc., US//US 2400:cb00:2048:1::681b:9cc2//13335//CLOUDFLARENET - Cloudflare, Inc., US//US |
pro newsletter archive | mapi: health research & commercialization services real world evidence rwe direct to patient patient-centered sciences pcs patient-centered outcomes patient logistics patient insights & engagement real world strategy & analytics rws&a modeling & evidence synthesis global market access data analytics & epidemiology language services strategic regulatory services srs pharmacovigilance mapi research trust expertise expertise in rare diseases expertise in gastrointestinal research thought leadership publications events webinars upcoming webinars webinar archive workshops apw stockholm 2017 orphan drugs and rare diseases 2017 isa texas 2017 isa glasgow 2017 wodc barcelona 2017 clinical trial study drug commercialization optimal market access pco 2017 rare disease challenges rare disease commercialization integrated scientific advice newsletters pro newsletter prm newsletter blogs patient insights & engagement real world strategy & analytics partners locations americas lexington, kentucky boston, massachusetts dundas – ontario, canada buenos aires, argentina europe london, uk maidenhead, uk lyon, france nanterre, france munich, germany europe (cont) houten, netherlands leiden, netherlands rome, italy barcelona, spain stockholm, sweden warsaw, poland apac india singapore taipei, taiwan japan seoul, korea melbourne, australia about us our company our history our leadership scientific advisory team careers news mapi partners global citizenship contact us login services real world evidence rwe direct to patient patient-centered sciences pcs patient-centered outcomes patient logistics patient insights & engagement real world strategy & analytics rws&a modeling & evidence synthesis global market access data analytics & epidemiology language services strategic regulatory services srs pharmacovigilance mapi research trust expertise expertise in rare diseases expertise in gastrointestinal research thought leadership publications events webinars upcoming webinars webinar archive workshops apw stockholm 2017 orphan drugs and rare diseases 2017 isa texas 2017 isa glasgow 2017 wodc barcelona 2017 clinical trial study drug commercialization optimal market access pco 2017 rare disease challenges rare disease commercialization integrated scientific advice newsletters pro newsletter prm newsletter blogs patient insights & engagement real world strategy & analytics partners locations americas lexington, kentucky boston, massachusetts dundas – ontario, canada buenos aires, argentina europe london, uk maidenhead, uk lyon, france nanterre, france munich, germany europe (cont) houten, netherlands leiden, netherlands rome, italy barcelona, spain stockholm, sweden warsaw, poland apac india singapore taipei, taiwan japan seoul, korea melbourne, australia about us our company our history our leadership scientific advisory team careers news mapi partners global citizenship contact us . mapi pro newsletter 2017 september pro newsletter printable version to request a pdf copy, click here. pro newsletter issues 2017 september 2017 june 2017 may 2017 april 2017 march 2017 february 2017 january 2016 december 2016 november 2016 october 2016 september 2016 june 2016 may 2016 april 2016 february 2016 january 2015 december 2015 october 2015 august 2015 june july 2015 march 2014 fall 2014 spring 2013 fall view archive share this page linked in twitter google+ facebook email 2017 september september 26, 2017 0 the patient’s voice in the evaluation of orphan drugs 2017 september by catherine acquadro | | no comments this article is based on an issue panel given at the ispor 19th annual european congress (2016). to view the authors’ presentations, go to www.ispor.org/event/releasedpresentations/2016vienna#issuepanelpresentations. the patient’s voice in the… read more 2017 september september 26, 2017 0 assuring success from regulatory to global market access of rare disease treatments 2017 september by catherine acquadro | | no comments we invite you to attend mapi’s workshop entitled “assuring success from regulatory to global market access of rare disease treatments” to be held at the world orphan drug congress in… read more 2017 september september 26, 2017 0 iqwig’s systematic reviews of guidelines are now available in the proinsight™ database! 2017 september by catherine acquadro | | no comments the proinsight™ database centralizes and summarizes published regulatory recommendations concerning the use of clinical outcome assessments (coas) (cf. glossary) to determine treatment benefit and to inform on drug approval and… read more 2017 september september 26, 2017 0 the journal of patient-reported outcomes has published its first articles 2017 september by catherine acquadro | | no comments the international society for quality of life research (isoqol) and editors are proud to announce that journal of patient-reported outcomes, a new open access journal, has published its first articles. read… read more 2017 september september 26, 2017 0 a new book! reproducibility: a primer on semantics and implications for research 2017 september by catherine acquadro | | no comments discover a new publication by kathleen lohr citation pellizzari, e., lohr, k., blatecky, a., & creel, d. (2017). reproducibility: a primer on semantics and implications for research. (rti press publication… read more linkedin twitter facebook mapi group is part of icon commercialisation & outcomes ©2017 mapi group, all rights reserved mapi user agreement uk modern slavery act statement transparence des liens avec les acteurs de santé contact us privacy site cookies cookies on mapi we use cookies to ensure that we give you the best experience on our website. if you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. if you would like to change your preferences you may do so by following the instructions here or agree and dismiss .
https://mapigroup.com/pro_newsletter/pro_newsletter_tax/2016-november
https://mapigroup.com/pro_newsletter/pro_newsletter_tax/2017-june
https://mapigroup.com/pro_newsletter/pro_newsletter_tax/2014_spring
https://mapigroup.com/services/strategic-regulatory-services/
https://mapigroup.com/contact-us/stockholm-sweden/
https://mapigroup.com/workshop/orphan-drug-and-rare-disease/
https://mapigroup.com/expertise/rare-diseases/
https://mapigroup.com/pro_newsletter/iqwigs-systematic-reviews-guidelines-now-available-proinsight-database/#respond
https://mapigroup.com/pro_newsletter/pro_newsletter
https://mapigroup.com/contact-us/buenos-aires-argentina/
https://mapigroup.com/pro_newsletter/pro_newsletter_tax/2016-december
https://mapigroup.com/about-us/our-history/
https://mapigroup.com/services/real-world-evidence/
https://mapigroup.com/services/strategic-regulatory-services/pharmacovigilance-risk-management/
https://mapigroup.com/pro_newsletter/pro_newsletter_tax/2017-september
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: PRO-NEWSLETTER.COM
Registry Domain ID: 1170532069_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.gandi.net
Registrar URL: http://www.gandi.net
Updated Date: 2017-06-26T08:47:41Z
Creation Date: 2007-08-21T12:41:29Z
Registry Expiry Date: 2018-08-21T12:41:29Z
Registrar: Gandi SAS
Registrar IANA ID: 81
Registrar Abuse Contact Email: abuse@support.gandi.net
Registrar Abuse Contact Phone: +33.170377661
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: A.DNS.GANDI.NET
Name Server: B.DNS.GANDI.NET
Name Server: C.DNS.GANDI.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-24T16:57:23Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Gandi SAS
SERVERS
SERVER com.whois-servers.net
ARGS domain =pro-newsletter.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME pro-newsletter.com
CHANGED 2017-06-26
CREATED 2007-08-21
STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
NSERVER
A.DNS.GANDI.NET 173.246.98.1
B.DNS.GANDI.NET 213.167.229.1
C.DNS.GANDI.NET 217.70.179.1
REGISTERED yes
La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.